Depsipeptides: When a Peptide Swaps an Amide Bond for an Ester

Most peptides are chains of amino acids joined by peptide (amide) bonds. A depsipeptide breaks that rule in an interesting way: it contains at least one ester bond in place of a normal amide bond. That single chemical substitution — swapping an N–H for an O — changes the molecule's shape, stability, and behavior, and it turns out that nature uses this trick to build some remarkable drugs.

Amide vs ester: the key difference

In a standard peptide bond, the carbonyl carbon of one amino acid is linked to the nitrogen of the next (a C–N amide bond). In a depsipeptide, at least one of these links is instead to an oxygen (a C–O ester bond), formed with a hydroxy acid rather than a standard amino acid.

Why does this matter?

• An amide bond can donate a hydrogen bond (through its N–H); an ester bond cannot. Removing that hydrogen-bond donor changes how the backbone folds and interacts.
• Ester bonds subtly alter rigidity and conformation, often locking the molecule into a defined shape.
• These changes affect membrane permeability and metabolic stability, which are exactly the properties that make a molecule behave like a drug.

Depsipeptides are often cyclic

Many naturally occurring depsipeptides are cyclic — the chain closes into a ring, sometimes with the ester bond forming part of the closure (a macrocyclic lactone). Cyclization removes the vulnerable free ends that enzymes attack, and combined with the ester substitution and non-standard amino acids, it gives these molecules resistance to digestion and a stable, well-defined 3D structure. This is why organisms — often bacteria and fungi — produce depsipeptides as toxins, signaling molecules, and chemical weapons, and why chemists prize them as drug scaffolds.

Romidepsin: a depsipeptide medicine

The clearest medical example is romidepsin (Istodax), a bicyclic depsipeptide produced by the soil bacterium Chromobacterium violaceum. Its structure includes both ester and amide bonds and an internal disulfide bond, and that disulfide is central to how it works:

• Romidepsin is a prodrug — it enters cells relatively inert.
• Inside the cell, the disulfide bond is reduced, releasing a free thiol group.
• That thiol reaches into the active site of histone deacetylase (HDAC) enzymes and binds their zinc atom, blocking them.
• Inhibiting HDACs reactivates silenced genes, pushing susceptible cancer cells to stop dividing and die.

This makes romidepsin an effective treatment for cutaneous T-cell lymphoma. The depsipeptide chemistry is not incidental — the ring structure and disulfide are what let the molecule enter cells, stay stable, and then unlock its active form at the right moment.

Depsipeptides in the wider peptide world

Depsipeptides sit alongside other "rule-bending" peptide natural products that have become important drugs — the cyclic peptide cyclosporine (with its N-methylated backbone), the glycopeptide antibiotics, and the lipopeptides. They all illustrate a theme: subtle modifications to the classic peptide backbone — esters, cyclization, unusual amino acids, lipid tails — turn fragile linear peptides into stable, cell-penetrating, drug-like molecules. Understanding depsipeptide chemistry is a window into how nature (and medicinal chemists) engineer peptides into therapeutics.

This page is educational and explains peptide chemistry; it is not medical advice. Romidepsin is a prescription oncology medicine used under specialist supervision.